DESCRIPTION
A man in his 60s presented with a painful and nonpruritic facial eruption of 1-year duration, which was progressively worsening. He had neither ocular symptoms nor fever. He had been diagnosed with chronic lymphocytic leukaemia (CLL) 15 years prior and treated with an intravenous immunoglobulin, chlorambucil, fludarabine and cyclophosphamide combination, with rituximab on separate occasions, but had suboptimal response. His CLL had been gradually progressive in the later years. Examination of his face revealed erythaematous papules and plaques, most prominent on his nose and upper border of his eyebrows bilaterally (figure 1). There was background erythaema on his forehead and cheeks but there was no telangiectasia, and there were neither pustules nor comedones. His nose was not enlarged and the skin contour of the unaffected areas was within normal limits. He had cervical lymphadenopathy and massive splenomegaly. Skin histology showed a dense nodular lymphoid infiltrate composed of mature small lymphocytes, evident in the upper dermis, with destruction of the adnexal structures (figures 2 and 3). LC is known to mimic other inflammatory dermatoses, depending on the site of eruption. CLL patients have been reported to present with facial eruptions mimicking granulomatous rosacea and rhinophyma. This is a less common presentation for CLL patients than for those with Hodgkin's lymphoma, cutaneous lymphoplasmacytoid lymphoma or B-cell lymphoma. 1 Benedix et al 2 reported a case of B-cell CLL that presented with necrobiosis lipoidica-like lesions on the leg in a non-diabetic patient.
LC has been described in patients with myeloid and lymphoid leukaemias, but it is more commonly described in patients with acute myelogenous leukaemia (AML) and T-cell leukaemias. Cutaneous involvement with CLL could be related to a more aggressive histological transformation or disease progression. This was the case for our patient, who had CLL with 17p deletion. This subset is often associated with poor response to therapy and high rates of Richter transformation. However, there were no blast cells in his skin histology. The prognosis is also less favourable in patients with AML and chronic myeloid leukaemia.
Cutaneous lesions in CLL usually improve with treatment of the underlying disease. There have been reports of cutaneous-specific therapy with narrow band UVB, conventional radiotherapy or electron beam irradiation. 3 Our patient was treated with a phosphoinositide 3-kinase delta inhibitor (Idelalisib) 150 mg twice daily for his underlying Learning points ▸ Leukaemia cutis secondary to either leukaemia or lymphoma commonly mimics other dermatoses. Recognising these variations is crucial as cutaneous involvement of these malignancies has important prognostic implications. Detailed history-taking complemented by a thorough physical examination are crucial steps in making the diagnosis. ▸ Idelalisib is an effective and well-tolerated treatment for patients with relapsed CLL and p53 mutation. For cases that are less aggressive and limited to the skin, cutaneous directed therapeutic options are available.
